|

Elacestrant Clinical Trials

20 actively recruiting trials across 10 locations

No change since June 2026

Also known as: ASYM-122762, C30H40Cl2N2O2, ER-306323, Elacestrant Dihydrochloride, Elacestrant Hydrochloride +10 more

Pipeline

Phase 1: 3Phase 2: 7Phase 3: 4Phase 1/2: 4

Top Sponsors

  • Stemline Therapeutics, Inc.3
  • Kristina A. Fanucci2
  • iOMEDICO AG1
  • Yale University1
  • West German Study Group1

Indications

  • Cancer20
  • Breast Cancer18
  • HER2-negative Breast Cancer6
  • Metastatic Breast Cancer4
  • Advanced Breast Cancer4

Other7 trials

A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Phase 2
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Phase 2
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
Phase 3
Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC
Phase 3
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Boston, Massachusetts3 trials

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Dana-Farber Cancer Institute

Phase 1/2
Ph 2 Elacestrant in ER Positive Uterine Sarcomas

Dana Farber Cancer Institute

Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Dana-Farber Cancer Institute

Phase 2

New Haven, Connecticut2 trials

Circulating Tumor DNA

Yale University

Phase 2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Yale School of Medicine

Phase 1/2

Daphne, Alabama1 trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Southern Cancer Center, PC

Phase 3

Springdale, Arkansas1 trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Highlands Oncology Group

Phase 1

Berkeley, California1 trial

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Berkeley Outpatient Center

Phase 2

Fullerton, California1 trial

Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Providence Medical Foundation

Phase 1/2

Denver, Colorado1 trial

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Sarah Cannon Research Institute (Scri) At Health One

Phase 1

Tampa, Florida1 trial

Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Moffitt Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Memorial Sloan Kettering Basking Ridge

Phase 2

New York, New York1 trial

Elacestrant in Advanced Triple Positive Breast Cancer

NYU Langone Health

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.